Cargando…

Neoadjuvant therapy with anlotinib in a locally advanced and pulmonary metastasis PTC patient harboring TERT promoter and BRAF(V600E) mutations: a case report

A 71-year-old woman with recurrent papillary thyroid carcinoma (PTC) was referred to our hospital. A computed tomography scan revealed extensive recurrence in the neck, invading sternocleidomastoid muscle, internal jugular vein, sternal end of the clavicle, strap muscle and skin; and lateral compart...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Yan-Jun, Cheng, Shao-Hao, Qian, Jun, Zhang, Ming, Liu, Wen, Zhan, Xiang-Xiang, Wang, Zhu-Quan, Liu, Hai-Dan, Zhong, Xing-Wei, Cheng, Ruo-Chuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Endocrinologia e Metabologia 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660997/ https://www.ncbi.nlm.nih.gov/pubmed/37364156 http://dx.doi.org/10.20945/2359-3997000000659

Ejemplares similares

Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAF(V600E) Mutations
por: Su, Yanjun, et al.
Publicado: (2021)

Clinical significance of the BRAF(V600E) mutation in PTC and its effect on radioiodine therapy
por: Zhu, Guoquan, et al.
Publicado: (2019)

Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation
por: Liu, Chaoyuan, et al.
Publicado: (2022)

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma
por: Gabler, Lisa, et al.
Publicado: (2019)

Mechanisms of TERT Reactivation and Its Interaction with BRAF(V600E)
por: Song, Young Shin, et al.
Publicado: (2020)

Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report
por: Liao, Lianggong, et al.
Publicado: (2020)

The thyroid imaging reporting and data system on US, but not the BRAF(V600E) mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC
por: Park, Vivian Y., et al.
Publicado: (2016)

The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAF(V600E) Mutation Status and Other Prognostic Factors
por: Czarniecka, Agnieszka, et al.
Publicado: (2015)

A constitutive active MAPK/ERK pathway due to BRAF(V600E) positively regulates AHR pathway in PTC
por: Occhi, Gianluca, et al.
Publicado: (2015)

HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
por: Cheng, Lingxiao, et al.
Publicado: (2017)

Matrine Activates PTEN to Induce Growth Inhibition and Apoptosis in (V600E)BRAF Harboring Melanoma Cells
por: Jin, Hui, et al.
Publicado: (2013)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

A Multifocal Pediatric Papillary Thyroid Carcinoma (PTC) Harboring the AGK-BRAF and RET/PTC3 Fusion in a Mutually Exclusive Pattern Reveals Distinct Levels of Genomic Instability and Nuclear Organization
por: Sisdelli, Luiza, et al.
Publicado: (2021)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

Identification of Potential BRAF Inhibitor Joint Therapy Targets in PTC based on WGCAN and DCGA
por: Han, YaLi, et al.
Publicado: (2021)

MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAF(V600E): An In Vitro Study
por: Fu, Hao, et al.
Publicado: (2019)

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation
por: Kwon, Jeong-Hwa, et al.
Publicado: (2018)

BRAF(V600E) and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB
por: Zhou, Dehua, et al.
Publicado: (2017)

Co-existence of BRAF(V600E) and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis
por: Ren, Haoyu, et al.
Publicado: (2018)

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
por: Liu, Rengyun, et al.
Publicado: (2018)

Papillary thyroid cancer organoids harboring BRAF(V600E) mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
por: Chen, Dong, et al.
Publicado: (2023)

BRAF V600E and RET/PTC Promote the Activity of Nuclear Factor-κB, Inflammatory Mediators, and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 50 Patients in Inner Mongolia
por: Zhou, Dehua, et al.
Publicado: (2018)

Claudin-1 Expression Is Elevated in Colorectal Cancer Precursor Lesions Harboring the BRAF V600E Mutation()()
por: Caruso, Maria, et al.
Publicado: (2014)

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
por: Čepulytė, Rūta, et al.
Publicado: (2020)

Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers
por: Wu, Yongxing, et al.
Publicado: (2021)

TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
por: Kim, Min Jhi, et al.
Publicado: (2022)

miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors
por: Titov, Sergei E., et al.
Publicado: (2016)

Association of ATM Gene Polymorphism with PTC Metastasis in Female Patients
por: Gu, Yulu, et al.
Publicado: (2014)

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation
por: Fernandes, Gustavo S., et al.
Publicado: (2018)

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
por: Seo, Takuji, et al.
Publicado: (2020)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
por: Bae, Ja Seong, et al.
Publicado: (2016)

BRAF(non-V600E) more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF(V600E) but without a survival advantage
por: Wang, Wei, et al.
Publicado: (2021)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China
por: Huang, Meiling, et al.
Publicado: (2019)

Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
por: Kim, Sue Youn, et al.
Publicado: (2020)

How do BRAF(V600E) and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?
por: Mukhtar, Noha, et al.
Publicado: (2023)

Preoperative detection of TERT promoter and BRAF(V600E) mutations in papillary thyroid carcinoma in high-risk thyroid nodules
por: Giorgenon, Tatiana Marina Vieira, et al.
Publicado: (2019)

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAF(V600E) mutation responds to dabrafenib and trametinib: a case report and literature review
por: Fang, Ruoxin, et al.
Publicado: (2023)

Glioblastoma in a female neurofibromatosis 1 patient without IDH1, BRAF V600E, and TERT promoter mutations: A case report
por: Cai, Jia-Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pjifepntktr6rf97orogp34csm